SEATTLE, June 22, 2022 /PRNewswire/ — LumiThera Inc., a commercial stage medical device company offering photobiomodulation (PBM) treatment for ocular damage and disease, today announced detailed findings in its LIGHTSITE III, multi-center clinical trial in non-neovascular (dry)…
News Ticker
- [ July 6, 2022 ] Hemophilia Treatment Market to Reach $26.9 Bn, Globally, by 2031 at 7.5% CAGR: Allied Market Research News
- [ July 5, 2022 ] Layoffs coming as VSP Optical Group closes lab in Olympia News
- [ July 5, 2022 ] Postdoctoral Fellow Research – Providence – Portland, OR Jobs
- [ July 5, 2022 ] Research Associate 2 – Providence – Portland, OR Jobs
- [ July 5, 2022 ] Industry staff shortage a priority for UW Medicine’s new interim president News
Copyright © 2022 Biotech Networks, LLC
